Product

Luteinizing hormone-releasing hormone (LHRH) analogues

1 clinical trial

3 indications

Indication

Indication

ER-positive Breast Cancer

Indication

Estrogen Receptor Gene Mutation

Clinical trial

A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors

Status: Not yet recruiting, Estimated PCD: 2027-09-01